Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.

Massey AJ, Borgognoni J, Bentley C, Foloppe N, Fiumana A, Walmsley L.

PLoS One. 2010 Oct 18;5(10):e13123. doi: 10.1371/journal.pone.0013123.

2.

DNA replication stress in CHK1-depleted tumour cells triggers premature (S-phase) mitosis through inappropriate activation of Aurora kinase B.

Zuazua-Villar P, Rodriguez R, Gagou ME, Eyers PA, Meuth M.

Cell Death Dis. 2014 May 22;5:e1253. doi: 10.1038/cddis.2014.231.

3.

Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.

Del Nagro CJ, Choi J, Xiao Y, Rangell L, Mohan S, Pandita A, Zha J, Jackson PK, O'Brien T.

Cell Cycle. 2014;13(2):303-14. doi: 10.4161/cc.27055.

4.

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.

King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, Cox K, Guo S, Marshall M.

Invest New Drugs. 2014 Apr;32(2):213-26. doi: 10.1007/s10637-013-0036-7.

PMID:
24114124
5.

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.

Blasina A, Hallin J, Chen E, Arango ME, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K.

Mol Cancer Ther. 2008 Aug;7(8):2394-404. doi: 10.1158/1535-7163.MCT-07-2391.

7.

The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis.

Peddibhotla S, Lam MH, Gonzalez-Rimbau M, Rosen JM.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5159-64. doi: 10.1073/pnas.0806671106.

8.
9.
10.

Checkpoint kinase inhibitors: a review of the patent literature.

Janetka JW, Ashwell S.

Expert Opin Ther Pat. 2009 Feb;19(2):165-97. doi: 10.1517/13543770802653622. Review.

PMID:
19441917
11.

Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.

Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, Wallis N.

Cell Cycle. 2009 Jun 15;8(12):1921-9.

PMID:
19440047
12.

The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.

Wang FZ, Fei HR, Cui YJ, Sun YK, Li ZM, Wang XY, Yang XY, Zhang JG, Sun BL.

Apoptosis. 2014 Sep;19(9):1389-98. doi: 10.1007/s10495-014-1010-3.

PMID:
24928205
13.

The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.

Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynaud FI, Williams DH, Reader JC, Collins I, Garrett MD.

Mol Cancer Ther. 2010 Jan;9(1):89-100. doi: 10.1158/1535-7163.MCT-09-0938.

14.

A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.

Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H.

Oncogene. 2005 Feb 17;24(8):1403-11.

PMID:
15608676
15.

Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.

Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao ZF, Tong Y, Lin NH, Sham HL, Wang JY, Sowin TJ, Rosenberg SH, Zhang H.

Int J Cancer. 2006 Dec 15;119(12):2784-94.

16.

M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe.

Evison BJ, Pastuovic M, Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR, Cutts SM.

Biochem Pharmacol. 2011 Dec 1;82(11):1604-18. doi: 10.1016/j.bcp.2011.08.013.

PMID:
21889927
17.

Chk1: a double agent in cell cycle checkpoints.

Yu H.

Dev Cell. 2007 Feb;12(2):167-8.

18.

Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.

Aris SM, Pommier Y.

Cancer Res. 2012 Feb 15;72(4):979-89. doi: 10.1158/0008-5472.CAN-11-2579. Erratum in: Cancer Res. 2014 Aug 1;74(15):4208. Cancer Res. 2012 Apr 15;72(8):2153-4.

19.

Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2.

Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D.

Mol Cancer Ther. 2007 Mar;6(3):935-44.

20.

The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.

Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J.

Cell Cycle. 2006 Sep;5(17):1983-8.

PMID:
16931916

Supplemental Content

Support Center